-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 TdG1hieiuJdeY2v8KllMu7BI5lRb291cGfypVIAOQImBQXGuzB+PQci02iqQ3+7H
 fYIyLO0B9MG4w3QI3IUngg==

<SEC-DOCUMENT>0000950123-10-103657.txt : 20101110
<SEC-HEADER>0000950123-10-103657.hdr.sgml : 20101110
<ACCEPTANCE-DATETIME>20101110094840
ACCESSION NUMBER:		0000950123-10-103657
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20101109
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20101110
DATE AS OF CHANGE:		20101110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GeoVax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		101178452

	BUSINESS ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080
		BUSINESS PHONE:		678-384-7220

	MAIL ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Geovax Labs, Inc.
		DATE OF NAME CHANGE:	20061002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c08150e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>

<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 OR 15(d) of The Securities Exchange Act of 1934</B>
</DIV>

<!-- xbrl,dc -->
<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of Report (Date of earliest event reported): November 9, 2010</B></DIV>
<!-- /xbrl,dc -->
<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>GEOVAX LABS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="32%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD>
<TD width="32%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD>
<TD width="32%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD nowrap align="center" valign="top"><B>Delaware
</B></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><B>000-52091
</B></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><B>87-0455038</B></TD>
</TR>
<TR style="font-size: 1px">
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD valign="top" align="left">&nbsp;</TD>
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD valign="top" align="left">&nbsp;</TD>
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">(State or other jurisdiction<BR>
of incorporation)
</TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top">(Commission File Number)
</TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top">(IRS Employer Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="48%">&nbsp;</TD>
<TD width="2%">&nbsp;</TD>
<TD width="48%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD align="center" valign="top"><B>1900 Lake Park Drive<BR>
Suite 380<BR>
Smyrna, Georgia
</B></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="bottom"><B>&nbsp;<BR>30080</B></TD>
</TR>
<TR style="font-size: 1px">
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD valign="top" align="left">&nbsp;</TD>
<TD valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">(Address of principal executive offices)
</TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">Registrant&#146;s telephone number, including area code: <B>(678) 384-7220</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B></B></DIV>

<DIV align="center" style="font-size: 10pt"><FONT style="border-top: 1px solid #000000">(Former name or former address, if changed since last report.)</FONT></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="3%" nowrap align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="3%" nowrap align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="3%" nowrap align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="3%" nowrap align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR>

</TABLE>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio --> </DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 4%">This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#147;registrant&#148;) from time
to time with the Securities and Exchange Commission (collectively the &#147;Filings&#148;) contain forward
looking statements and information that are based upon beliefs of, and information currently
available to, the registrant&#146;s management as well as estimates and assumptions made by the
registrant&#146;s management. When used in the Filings the words &#147;anticipate&#148;, &#147;believe&#148;, &#147;estimate&#148;,
&#147;expect&#148;, &#147;future&#148;, &#147;intend&#148;, &#147;plan&#148; or the negative if these terms and similar expressions as they
relate to the registrant or the registrant&#146;s management identify forward looking statements. Such
statements reflect the current view of the registrant with respect to future events and are subject
to risks, uncertainties, assumptions and other factors relating to the registrant&#146;s industry,
operations and results of operations and any businesses that may be acquired by the registrant.
Should one or more of these risks or uncertainties materialize, or should the underlying
assumptions prove incorrect, actual results may differ significantly from those anticipated,
believed, estimated, expected, intended or planned.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;2.02 Results of Operations and Financial Condition</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">On November&nbsp;9, 2010 we issued a press release reporting our results of operations for the
quarter ended September&nbsp;30, 2010. A copy of the press release is attached to this Current Report.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Exhibit&nbsp;99.1 Press Release
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; text-indent: 8%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Dated: November&nbsp;9, 2010
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><BR>
GEOVAX LABS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Mark W. Reynolds
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Mark W. Reynolds&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c08150exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">


<DIV align="right" style="font-size: 10pt; margin-top: 10pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><IMG src="c08150c0815001.gif" alt="(GEOVAX HIVAIDS VACCINES LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GEOVAX LABS, INC.<BR>
ANNOUNCES NINE MONTH 2010 FINANCIAL RESULTS</B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B>ATLANTA, GA, November&nbsp;9, 2010 </B>&#151; GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based
biopharmaceutical firm (the &#147;Company&#148; or &#147;GeoVax&#148;) developing vaccines that prevent and fight Human
Immunodeficiency Virus (HIV)&nbsp;infections, today announced its financial results for the three and
nine months ended September&nbsp;30, 2010.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">GeoVax reported a net loss of $644,666 ($0.04 per share) for the three months ended September&nbsp;30,
2010, compared to $230,815 ($0.02 per share) for the same period in 2009. For the nine months ended
September&nbsp;30, 2010, the Company&#146;s net loss was $2,268,544 ($0.14 per share) as compared to
$2,440,977 ($0.16 per share) for the same period in 2009.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Net losses were partially offset by revenues related to the Company&#146;s grant from the NIH in support
of its HIV/AIDS vaccine development activities; such revenues were $1,163,288 and $4,239,017 for
the three month and nine month periods of 2010, respectively, as compared to $1,808,551 and
$3,271,506 for the three month and nine month periods of 2009, respectively.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">As of September&nbsp;30, 2010, the Company reported cash balances totaling $1,426,342, as compared to
$3,515,784 at December&nbsp;31, 2009.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Dr.&nbsp;Robert McNally, PhD, GeoVax&#146;s President and CEO, commented, &#147;GeoVax continued to make solid
progress during the third quarter of 2010. Our Phase 2a clinical trial for the preventative
version of our HIV/AIDS vaccine is on schedule, with full patient enrollment expected by the end of
2010 and trial completion during 2011. Our Phase 1 clinical trial for the therapeutic version of
our vaccine, for treatment of HIV-infected individuals, is also progressing, as we continue to
actively recruit patients for this groundbreaking trial. We have screened numerous individuals for
meeting the stringent enrollment criteria for participation in this trial and have selected a
handful of candidates for continued evaluation. Once a candidate has achieved six months of stable
viral control while on drug treatment, they can then enter the trial and receive the first
vaccination. Our pipeline product, which uses an adjuvant to boost the immune system response, is
also moving rapidly through the development process. We have completed preliminary discussions
with the FDA and plan to submit an Investigational New Drug (IND)&nbsp;application in early 2011, with
the intention of beginning a Phase 1 human clinical trial by the middle of 2011. We are very
excited about the prospects for this program, as the preclinical data are very compelling.&#148;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Dr.&nbsp;McNally continued, &#147;Our primary focus is on accelerating our clinical programs with the
objective of generating the necessary data to demonstrate the efficacy in humans of our vaccine
candidates. To that end, we are also directing our efforts towards ensuring we have the financial
resources available to achieve our objectives and make the appropriate commitments to our programs.
The federal government continues to be a strong supporter of our efforts, through significant
support provided by the HIV Vaccine Trials Network (HVTN), funding through our Integrated
Preclinical/Clinical AIDS Vaccine Development (IPCAVD)&nbsp;grant from the NIH, and through the recently
awarded Qualified Therapeutic Discovery Project (QTDP)&nbsp;grant. We intend to supplement these funds
through our own equity financing activities.&#148;
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">Summarized financial information is presented below. Further information concerning the Company&#146;s
financial position and results of operations is included in its Quarterly Report on Form 10-Q filed
with the Securities and Exchange Commission.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>MORE</B>
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>GeoVax, Inc.<BR>
Add 2</B>

</DIV>

<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B><I>About GeoVax Labs, Inc.</I></B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt">GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human
Immunodeficiency Virus &#151; that leads to AIDS) and other infectious agents. Our goals include
developing HIV/AIDS vaccines for global markets, overseeing the manufacture and testing these
vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety
and effectiveness, and obtaining regulatory approvals to move the product forward. All preventative
Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA
and MVA vaccines, their ability to raise anti-HIV humoral (antibody)&nbsp;and cellular (cytotoxic T
cell) immune responses, as well as, the vaccines&#146; safety. Successful results from Phase 1 testing
supported the initiation of the first Phase 2 testing. GeoVax&#146;s Phase 2 human trial began in
January&nbsp;2009 and will ultimately involve 300 participants at sites in the United States and South
America. Recently GeoVax began enrolling patients in a Phase 1 therapeutic trial for individuals
already infected with HIV. For more information, please visit www.geovax.com.
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><B><I>Forward-Looking Statements</I></B>
</DIV>


<DIV align="justify" style="font-size: 10pt; margin-top: 10pt"><I>Certain statements contained in this release, including those relating to postponement of the
offering, as well as statements containing words like &#147;plans,&#148; &#147;expects,&#148; and other similar
expressions in this press release or the Company&#146;s other public communications, are forward-looking
statements that involve a number of risks and uncertainties. All such forward-looking statements
are subject to certain risks and uncertainties that could cause actual results to differ materially
from those in the forward-looking statements. These risks and uncertainties include, but are not
limited to whether: GeoVax can develop and manufacture its vaccines with the desired
characteristics in a timely and economic manner, GeoVax&#146;s vaccines will be safe for human use,
GeoVax&#146;s vaccines will effectively prevent AIDS in humans, GeoVax vaccines will receive regulatory
approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine
development, there is development of competitive products that may be more effective or easier to
use than GeoVax&#146;s products, GeoVax will be able to enter into favorable manufacturing and
distribution agreements, as well as other risks and uncertainties, such as those detailed from time
to time in the Company&#146;s Securities and Exchange Commission filings, including &#147;Risk Factors&#148; in
the Company&#146;s most recent Form&nbsp;10-K. The Company does not undertake to update its forward-looking
statements.</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 50%"><B>Contact</B>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 50%">At The Investor Relations Group:

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 50%"><B>Investor Relations</B><BR>
James Carbonara / Jason Strominger<BR>
or<BR>
<B>Public Relations</B><BR>
Janet Vasquez / Robin O&#146;Malley

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 50%">(212)&nbsp;825-3210

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>MORE</B>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.50in">




<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>GeoVax, Inc.<BR>
Add 3</B>

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GEOVAX LABS, INC.<BR>
Condensed Consolidated Statements of Operations Information<BR>
(amounts in thousands, except per share data)</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">Three Months Ended</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">Nine Months Ended</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000">September 30,</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000">September 30,</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2010</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2009</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2010</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2009</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Revenues:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Grant Revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,163</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,808</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,239</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,271</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating expenses:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">909</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,470</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,020</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,530</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">General and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">904</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">574</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,508</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,204</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,813</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,044</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,528</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,734</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Other income:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Interest income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(645</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(231</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(2,268</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(2,441</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Loss per common share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.04</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.02</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.14</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.16</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>GEOVAX LABS, INC.<BR>
Condensed Balance Sheet Information<BR>
(amounts in thousands)</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">September 30,</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">December 31,</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2010</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000">2009</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Assets:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">1,426</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,516</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">711</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">365</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total current assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,137</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,881</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Property, net</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">256</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">344</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Other assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">600</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">90</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,993</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,315</TD>
    <TD>&nbsp;</TD>
</TR><TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Liabilities and stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Current liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">847</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">571</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,146</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,744</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Total liabilities and stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,993</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,315</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Shares Outstanding</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,655</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,633</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt">###
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c08150c0815001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c08150c0815001.gif
M1TE&.#EAXP!2`/?_`&N9OIV^U4R#L?K\_,G:YEF+M>SR]G2=P<78Y:S)W/CZ
M_%2)M!U@FA=8EKW2X:G%VG2AP[3-WEV1N>#J\:/"V/+V^?;Y^TJ`KL'6Y(VR
MSOO\_3!MHU&%LH&EQ9FYTKG1X8&IR.;N])2VT/7X^J&^U=3B["5EGFJ5N_CZ
M^TI]K'*=P='@ZY"QS;#*W3ESIGVFQ2EJH8RNRN+L\M;D[6:5O#5SJ+;.W[W4
MXV&1N7ZCQ):YTFV=P*'`U[K.WXFMRH2GQA99F(:LRN3M\Y&TSNCP]2!BG!I<
MF35QI:3!UL36Y+',WB)DGC%QI8FKR3EUJ"!AFQI:EAA8E3UUJ,'4XQQ>F*S&
MVD)^KBULI-[I\#YYJK3*W2=IH=GF[LS<Z(:IR$5]K4!ZK/#U^$%YJ\[?ZAE9
MEGFEQ=+A[,K<Z"UMH]KF[ER.N(FPS?K[_._T^$6`KRUJH?7X^2]OI?S]_=SH
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MYYR\U'";P1=6D________R'Y!`$``/\`+`````#C`%(```C_`/\)'$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW'A0`P)Q34*22$6-H\F3*%.J7/DOD:]B
M_?HQ,#;"'\N;.'/J3"E'$K28\[3L'$JTJ%&%)<#%?%:GU-&G4*.JC'9@5<Q;
M%*))W?K47S0Y;"ST,4!$QIP9Y+H@2'*IAY9-53`A&:9)UI`A&8+`VLL7UIJ[
M0SQH"H`$4Y5-6GI<2D+@EQE"6(00:;/(P@`YT6PBG"$E9C\!B+B*7NEO&IL^
MH!YU^?!`!PLO.?+PHZ&&@Q4G:#P584"L6!1H#8(+!T*\N''CPAL`"?XL2K$_
M#(J\8L+LP@()E0[DZ=!DR+X$-U9D_X,$9\!70+5B-AA2<K1[B_[D6$AEYD,`
M"*8XI/@BIL853[7\40PTT%A38#75//.,9PPVZ."#$$*H(((&$A@%.'\4L44<
M3H"10@H<.$"$&J[$!`41[Z6H4'P6E(+%+Y<@`P@$AM#Q!SA[$-<`--)($V&$
M/2)8C3765$.@@L^XXAPX4!#S!S%01ADE%."`$X4KTD#S#($&$IG@,SY&"`T:
MG?1`14S0[-"'#F7LHX4Q9LB`B`+3:*8B5'+T@<4-`301RRX7P'"C<#S^V*`T
MSZR2G);%U.))'':XP8$:]`"@0BQYY)###S\T$4,,+(0JZJ@L?-J$%S]TD`,G
ML:@```T2+/\@`!B\P%`$,:XHFER2>/11R4_]/.%`%U<$!PX#3`A`0P[<4'"&
M#'!H=6=._@P@Q`VHJ'&!&'$4`<6!81JZU"K&04/,*_E0`D$OFF"B12))=$$.
M%UC(0(0!;0@R@B,*L*&!''),,TTT!!=L<#0"`ZS!`&PX8H$@82!"A!#9<%'"
M+PA<$@$R)`SQ@BE\Q('&`XBD$Y,T!83`@E*>41C%'R;4<$P*`"132!MRV#GM
M1?$)@D4A6@1AR"O*`5&HN/T,"4T45,!00Q8IA)*+.^Q@@,TX%F"V\T!>_9M!
M`S&EXX$<`C03QQ+$_':T9]*0"P04LTC@@0W:A##"-%L_%,TBY+#_$X,*%VP!
M#G-(MQU<%+J`H<8!/P#20B%8A,%&G7DOE,H%GDG!132@S'`(#]SD`,`"]E`!
MW([A9AD<,;,4$`L+-PC!1N4'36.`$A"$XH0)4"`8[H_0%!=,/H$,HT477!`Q
M@@;2TMZ0/PGHL=0.<A!4&AMA"%'"%#)*P`L4Q?TN38)_Q'%,`3J48$'>T81!
M2"(@9&'$<K]'>(TU411QQ#$+W!&!#(YHGO,H$H83A,D(<W!(:191@@?D#@Q,
MJ$44K+$@SSR#./6H!`D(0`0VZ&PKB]"&!P"0A3_LJ'#!^8,D=I&#4R`@!`/X
MX``KTH4W+$4`>)-(-"P@`PR((`<X8(()_X&1NAUY0@T_6`<1JA>5:<@@``)P
M0CJ@40T4`H$!E!!!(@AA``_.T"1#8)DKSH&1:"@`$BOH`2`$P`#B5+`?B`*'
M+KZP@QO,CBC^J,`*SN&&'+WQ1PDJ@A,NL`9M+$*&7]R(!5[AHV]<``LGV5LG
M[L"!9CPA"F^4AG)@$(AU<,&++(E&*EJ`AQI``6SB`DX]K'"`4YCAD(ED202`
M!84@W!$ET1C!#/P0"P%0X81H:@`5P."%&U1@)7T00>`4A+3E\&((4WB$(-K#
MD/B@@Q`80T`A6L'-;K:B!-A8Q%$L@``EV,`&'[`$(AV"`E&$R1=)P,D.L]$#
M$#"!?A8DQ@8X\/^!]7%$`6<`@0G`4;\'-4</Q[A#"30`$0580@L`0$,QCD-1
M(+`""$MP@`!U$HTQ5"(>Q1D"0R7B#P=LX&3>&`!1--"%0%Q@"0BR(!".(`(L
MJ/0B&AB#%^+0@#]""!JKF,4!'B"$C2XD&MB0AQ6,@#JD]0,:%TC%42SQA<S-
M8"(*``$4U..`HTP#%#P@(3&L$LP+`"(;%K$`+(1!!9\^2!I`:$00"K$(HR[$
M`J?X0N^<VB`73.(HT:@"*I4!"+LN9`Y5A>,L%`"5]A'B`79H@#4L^`0Q)."6
M#T'$`XX`!*0]HP@7\(`_(Q*-.10`E3&Y!C3`L0087.&UL(7!%F:[!4__$,,)
M9GB*')S@(VEP0`82(4&)^@&.3(B&#1@0Q1NBP+8]A.BFU<S&"98`K!\]`QQ?
MR$11)Q(-?1ABLB=K0!Q.X(53*($1Z$UO"Q+`W@0\P`>&:`54/,#<?M3"!A&1
MPP4JZ(L5N`<%2J#!+<C:CU7`@`527<@T$,`!MSYH%;KH!2%R.)$26(%E_6@`
M'8+0"D1H8)W6DT,A$O@4,PC#1]#(!8@/8@EB>`8/XG1/-!#A`"N@5AK!H`%:
M$Z(!/WCB&N*2A@G4T(Z+$,$G,?G&$@X0@A4C!&%08<,/MDK<"3Q$`P"H8C]@
M8`,G0\4"/`!#=8$QBU\PL2`#(`$#'-P@:/AB_QAMN,@(\H#:*V0`L\[S!P9.
MVH]G!,&P!B%$9V+"@3A/*QHS\$9ZT.0$!YQ9(-.H`AV0!@U[=`'/$J%&%:07
M$UWX8;1?M,`"PI0"4#1D&K((AGK\0,UI$4$5GO`,.+)PU8%0`P%Q**B#E$$/
MX&)D`@V."2N2`6C:)8%E8J-P0D(PZIB8``ZT\\<--E!!:/B@>=@H@):!IV,O
M-^0<+NYS`:`;RW^PP045Q(%3%O*!)RPE#]X6C3^TX((P%<$2`HF&"HP@KF?4
M0`CQ/BH?*O@*#.C$'P%/",+7*8(*Z@$!#-D!L(HPA8-\A7F:\0<;4,`&\^0;
M!1QG@\@?G9!H,$SD*/]PA+(9P@9VP$`]>-#*!,0LK@T08".#`%8Q<@#JD[`A
M&UK@!LCX(`%5;*($W?"V''"!`%D`P!!\H$09UK$"1#2/$))`DPI6#(H_Q,05
M)PB-0%`0B74`0!)+>,(L#"&+))1B`A+8C220(#`A`*`1#*A%+;;@AQ@?Q!\V
M^$+>&4`%;[1BI'I#!4SZ`08K5R'6AOH#+'IND5,`JQ$M2'A$L)`!`8!C.<D!
MAS!`<`;$(P2O:KA%<I3#BB/0HPHCM4`'6+8$0Q^$&D-`93U(@#=_A$`>\MN1
M@D[G"7H<`@%'>(8U&$`(@?1A&&_0$C3T0`),"X00Q5+0*``0!HI80`P+\L3_
M`_[!C<7_R`7RU<@T:`#D?M`B!"GQQQEL$0\V7X,8PO``H&4P76BTOT'WHPOJ
M$!HEQ6<-<`KKU`:A\`TQ80MH%0T(L`!0\'^'`@U,D`<NH!X4,!`*4`4$Y@N%
M<!`5X`T5!`X`D&`4@00P40S<0'[F!R'2@`,D9Q&+@#DQH08S2!!@(7(\V(,\
M:'H"80%^H`OA@C]4("#6\']`4`8&<!`80',Q40U10`Q4``X)XAG0P`$E8&[N
M%!,IT(0&$0WL8`)H`@O4$`T\\`K_5PU0L`2>0`51\'^HM0JG4!`98#)]Q@NF
M1A`C``)>UV=J`(85P05@T`\L^`\/`'D1T@`ZP!&@_W`,2P$/Z^0/)0`;FG*)
MF'B)/Z`/RO8`;]!^T#`/:M`!=^$%G_`&X-4/1:`*QT00$R`&P+(E`A`(W``(
M3<`/=-!3:,(!W><`J*0+Z]!J`A$&>%!?5#`!_I`$KP!>T/`$G]`$I\`.@,`)
M-5!=GD&'!4$$NT!ET'``W3<0/7`%/O(,6Y!;%]$&`"`-XO</,\=FZA$!'/&*
MZI$,"6$&'``.!)*/^JB/46`%&*`9!O`&%=0`5C`%'72&<F``!+`#G143>I`(
M!&$!)U!!UX`&LC`!*A<?%:`/E;`$81(%+R`'"I!KAA@+@F`0G<!GT+``TR`$
M'!`FT)`"6H`(.>,5%D`.*O\0#PV"C01!#9SA&?/@`;$G!?A@(K(@C!-A`;$@
M#8WW#]&`!ZSP(PV0`!R!!;:@'G5X$'+P`\-5.#G`6(Y@"A44##E@>P7A#R3`
M:=+`!(X@$'+@!T5P,@LP`X@D!T_H&6]@`]1``E1&!R%8$*H`+,K0`X[0`=P(
M`&9)$-&0`$O`(#Q9$*V@B$M0!?^P"`"`2G_P`GYG$8)P``UP`-+"!0N0B@X"
M#7>@>0HA!+00$]:P!HBD`)S0(T@RFTCR.P=PDGO&F@``"0IA`6O@;AGV`0(1
M`@4PCG%0:PA!#3?``#$1!;WRDWW6"P5A`1O@(]?P6YPQCBF0F`5!#4'PAP66
ME6?_F0&+]@S"@`5(P&G/<`'XEA$3(`!+`$GYU@**^"`%@`(;80#+,#UV!9L-
M``54$*`".J#;P""W*0=#\(=4H`\,40*#!@UYH!4$H`LQ40P@X&1RH`8+(@U9
MP`7$.(Y@8'J=4%_@T`&.H`5_R`!(P!"$L)\Q\9@%D0T<4%_0<`(IX!E1<`[%
M!A'&H`<JH&R"H`[\!B$N,`8;@0*AX!D<@)\&X0B<0`.+D012.J53V@/UX!FW
M64`HA@,K5SOPL"#?$`KBA`3UU0Q;R!`.<*7]0`R)$`X/P&E08([_(`=X`"P;
MX`#^$`@_(0T+(`0,,0`^$&XP2A`+Y@N>X0K#A0\`8'T3_^$/I@`#?QF1@1!N
M#E(,!["9%D$-$``L4H"<!($",X"I!N$/;J!EM\D%6>`CQ-`#3P8PKDH.J&0+
MV/`/O](/KO"5#5$*..`CJ\`"_U`!'+`4IG!'*Y"!<"0*;!`-]@!DQ"`..6@0
MK6"L@VH]$:"3#!(%'&!E&<$&`<`++="E_S`">,``#.@@C0"/&O$!J/0$P]"E
MT_"LUF,%%72;O[`%,8$&Z:>8A"`+(=&O!^`9Z.</^>`C5"`".RH0;-`!)>(*
M._`/_A``J%2D<\H"RH`FPHD"P*D+">!MB'"CX:D0TU`&9^(9OJ!1VUH%_`2N
M`H$(:V`"!24-OB"(%Q$&(^L*WO^P;B0EKS%QFP2@IF#0G@0Q`VQ4)41K?L+0
M"M0P"SZR!!2@=$T`$\^0"P+1!L!)"BP@!\396VC0EA9`"C&Q`0;7$"-@@]-:
M$)/@!`S"`="6$550!PB`E&?9!;9`!1389\LP`RH;$2H`+'^PHHVJL_UPFX5`
MAOU0`YXJ$+V`6@\B#.3@#[S@(T\0`-ZF`3\`M94P$"#`7-+P2!'PA^`0`&.G
M:EN&7PU1`1Y;M@,Q#5[P@@RP!I0'$=10"A2@"B?I$);P`GI`8!4:"EV0$1B@
MGDZ`(CD[KX)@!DP0$T\`<04!`%;1(\[KO`T@`$3@#PL`-N#0!/!*$(N`!R6R
M"B`P$`C_T`@Q\0>84`D5Y`)G*@=HX".UH`,'^P^6<)4?BQ#2-K)LLP&D2Q%8
MH`0W\+X$(0C&X`9`\$>NX`)G@)H%T08&A"9X,`+#N[."(`3-%@4>8!````36
ML`U$2[3$D`]=H!5!\!.N4`<RFQ"H>C)DM+*?X!D;(+JN$`L.[+!J(,*76DT4
M<`LO*IX&\9YAL@K``K/<V1!R@`TE8`!YNQ`*H`0+0%ULLP2P(`,(/!!CT`R>
M00QX`'\0X0^`>YL)NW@P4,([<`!8``=D7,9P8`$4E@C.$!-4L`G5Q`)AT@B]
M*Q#^\*8.`K8$<0XLXPE=M1!9F\,(80"?4%]1``$`\(?/L`![__@0`V``KQL1
M_M`&?E``Z8!:Q+``A\"HI\8#U?4'W@#%#Z'%Q.L/$6!#3]4!,>RP#[#("H$%
M%S".Q\";"F$&]@I')$P0EW,H!9#*_S`)]=9GH=`'*Y(!]ENV_B`"S)DTH3`"
M:3!P80,+M?L\6J,1<@`*B;``.8(F&Y`'OC81;*`"!"8-`F`#FGR66WR2??"2
M5P$(_N0/B.!M`]`+B/P)PCNJ,Z#._6`"/*!LT9![#-(`2J`S%L`)BQ<%WOAD
M+4"AUZC#`_$(1!@3<6!PU-`%X*D'0K$BT\P3CW`'8F`"F-0`M<`")="6$H$(
M@2"Z<$20ZU`"I:```2,P,`W3<F`%8?]RFP(Q`R[[=1+P"V%0DPOWTPM'$`90
M`.WG"F!0!9#P85ZA`"5@3V&BJ$Q*$'TP#VQS!$#(C@(`DQ<0`32)<#O4"A`0
MEX[)T/\@`U\0)K=``F?V`#@,1[5@!A^DD8B0"A80Q1`1#3*`!`=P!.2R!\WP
M`B5`;@Z1"EZ`C]>(?RSD!3'`#8S=V(P=`YP6N+7K#VM0!.6Z"AL``#$0`*?0
MV9[]V110`F?6!5M0;52``U[@!Z<@`B_0#)C$FLW0S=:SJ<T)"']W`Q[)FD7P
MC*H]!($@#-8(R%(-#R.["B9)$&%0!J.P%(:`MPXK!T*```@P`T1PU2L1#8+0
M"D@@`<0`!'O_X`0`\`O^.Q""(`);H+C/((7%("7LC2M8FLIM4`;OX!GWDR%%
M<-_XG=]+D`68P$34P`Y;L(90\`1+4`O@\$;6X`0WD!"7X&[?X`OY6A#3$`!+
M(.!%L`1P^$9',ZA:0+BK@`:L+!!"L%_C:PL0@`H0H`:H\`LAP%A'X0_CT`)U
M(`8PL`=\$``K,`+^2PW8```P$(=\Q2!X\(UNR0.^``YU^R/7T`S(V5T2F.0M
M4PLX0`@@A@@GX`K%T`'=D!#3<`/W".7:?`#&"@T9H!ER0`!4$,?&@!"@P&?/
MP`JS(`"]@(RB(0=8L`Y>H`974`,00`)SD+T$P081$`MV\`S,09N(_XXDT)`%
M9VIK28`';W#HB4Z;5."W=/Q[64`,PJ<@P5$$;I`!0:R8)'`+5X"G*Y(-.>`$
MK+#IAMX`2Z`&C(`"0=!3J\`!I@8'50#<6U($W/#(_U`%&U`,`B`/2A`&<"L5
M_J`!H/`+FZ`"3I`%HJ`$H'#$`D$-@L`%R``"AC`+Z:!WWO[MW\X`#&`*%:`S
MU!`&72`"E!`'X-[NWHZ^RN8(,U`%E6`/15`+KV`%JN``-M40(UX`HGH0%C`)
M#V`*3'#OK\`'&7`#T_L/!@``!7X+`&`#.]`(5*!W17`'LGQZ!-`#V>`(40P6
M#AO4-R$'1$#O')`+[``Y=U--.^B#,,^#*/\00_1K&C$?\RA@6-&@`?X2#A+Q
M+Y`\#0R3,P9!#3R_<2,0<B(GV"D1!AC@`(_`#C-P`_3(48XP"$IP"E7P`1A0
M`CACU^46]@/1!AAP!O=0!24P%T8Q#18`"C(P"(10`G/0!AXG]G8/$8X@`S*0
M`*UP"C:PX,@>#2BP"(O`!D1_]XB?$&'`&&F0"E40`H_P'OY`#6"?^)4C\C]M
M^9J_^9S?^9[_^:`?^J(_^J1?^J9_^JB?^J.:&1OA%96O^EPA`_!0!?YD`?*0
M#`8`":Q=`>L`#WLX#4EP!U6`-U60"]V,!3X`#UC\#R6@"L.@`1;@`2\`#_"@
M"E6@K?_P"$-@"/;_8`@>0.0JT0FJ$`&O#_L'P0-&H`Y;_@\SL`=J@`OZL`2S
M4`$'8`3*VPYJ8`0?X!4"`!"Q!/W[YT\%D#TM"$8#](Z>'"YV1L7A5<0(!TC_
M1H1B0$F%%2--!A`D6=+D290H_6FII"3E2Y@Q9<ZD6=/F38+4`##0$8T@!7"<
M%&AA16/`CSTN_]EXLD#.OQ`P'E`CR*7(*P:P_/UCTP$<#W\1Z"P[0Z[%L0:J
M_"'8<T)&!7U.P`PBZ2\:U8+1?'*M8&$K20T5V/S]1PW%HJ<%+1@88-?N"+]U
MX<"95C<P"KPX-6_FW)EDA10;E"!"!$G"DTS4@K`B$6V(.1W^V.331>!?_S18
M%]H0;,,!C`TQ!9Y"PL'*D@9NQ,IL]4=A22@4'_9XB\0F6@@9;$ABF=6+S0`=
M3#Y`RF#BR#PU,_P9R-!HB:<#??QEJV1BR88`(R!58J8A@B0()*!B'E10D(,`
M2AAXPHU?HK$@"%YJ\*22$#RS\$(,3^)"BG@XJ*227?38``-_#*'"`7].60(>
M?QAA184^_C'@`EA\DH,$3WR`9)D+POAG!B>"L:"46%AAA*0;-KA@R&:,N$`>
M3(@PJ90]#A`$&S?`6&2?66)``!!6FI`#GB4^H:"2(KB!Q)0W5.'A@BT06"$.
M`>1H`HHC>OGA(ADFH<4-#V1Q0@`B;'AGAT)@B?_#A@P;=72S"&`@!08Z9O$D
M"EJR,X$),Y:"H1(X"O"%Q'\BM80@+`28!1$40A$#BW^FJ$41:L8H`!PA2$I`
MEP(&:P6$./;PY`(X2F*C'AH0(8$!3**9@``4V/@`G!C:**(`&?P1XH%$2#`!
M'@7\*8&'"2XQPH<1#@"G!SE&H$(-4'P8A00X*@"`"0R2&:6`7\(PPX!'`Q88
M)CFX^0.>:?1Z0(\%V,`&&APR:L6%!9+119W*+(C%#:JH`:$!9DX1X8@-/OB'
MA`:"2)$.&#0@2)!8]A"AC3D&DD.?"_8(H"1JF%&#"QAH,&`$&P``PQ83=&GA
M!B-B2.P?!3AI8`Z39('_0@L9.*#C*2S`R<$1>](1IAD[P#`$@Q$DD*0()Y30
M;F"XXQZA2)/_*=B(._Q)@!5.'/E'!EO><&&)7/\A)`L2"++D/3L4*<>3=/PP
MB)4J-/""&`D(TB"`-PA'PHT`MII&G%%0(<P?4^R`@(X(HK%ABQ,*28.#9F90
MXITAJ)EFA@0,B,454`KZ``$+:-BBBT[H,&6K=>(!1(Y9!$"`$$)*("2,$/R5
MA0X[N(C[>X%#N+7PN<%A9!H(J!C")T12<`4<>?YJH896_AD`@")4(80++GH)
M4PY[%`$!?<`#.-S@AS6H`0;O$`$U6@`#)]@`%`ZPPA[.8!(04($!:AC!/X+P
M_P<;1"-)%ZB`-O;P"2*8P1!Q@,,/P.$'"S@@#O*``QH$,($>$$,$A5F=#?RQ
M`"8XP!%(,`0JSD`)$&A@&HK@10G`]\1&F4$13DB,$';!A%180!16P`!!V.`-
M.GGO']-80!Y&$(T6V($&BR#)+^+@A5)L@!+9R`8EXG!'7H"A`(=XB@94(8QX
M-*`(S1`!80A2A3C4`%;_N,01GL"'+]3@!-.81B6NP(!;N`$!AI.`"9P!`[<8
MX`H@&,$^-C"%?SA"%`N8P#^Z\(4E/.$*"X"#!0ZP@2,P(0N9>!L4?=F9,&#@
M%W\902$P,`TVG$$?';Q-"6Y`B,3(@04$T!T7;M!*DF58X`8S6(0#S,"&12#@
M!N-,@B5Z.49MR*()P^#"TTB2BAL4XB\#*`0+$B`$?91@*X)P@#B0((2]M($"
MW&B!!31R@T=$PQ(8B-$`SM`%ESF+!.*P08RX\@%QB`":O^1H1SWZ4?`%!``[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
